Immunome, Inc. (NasdaqCM: IMNM)
Health Care · Biotechnology · US
$28.52
+4.85% today · +187.5% 1Y
Immunome, Inc. (NasdaqCM: IMNM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.24B and employs 206 people.
Over the last twelve months the share price has gained 187.5%, trading between 8.67 and 30.06.
Tweenvest scores Immunome, Inc. across four factors: quality 29/100. Its strongest factor is quality.
IMNM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.24B
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -2.49
- Dividend yield
- —
- Beta (5Y)
- 2.12
- 52-week high
- $30.06
- 52-week low
- $8.67
- Avg volume (3M)
- —
- Shares outstanding
- 113.58M
- Employees
- 206
- Next earnings
- —
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
- Founded
- 2006
- Listed since
- Oct 2, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.